ABSTRACT
Background Introduction of pneumococcal conjugate vaccines (PCV) reduced the cases of pneumococcal disease at global level. However, there is an increase in clinical and economic burden of PD from non-PCV serotypes, particularly in pediatric and elder population. In this study, immunogenicity and safety of the BE’s 14-valent PCV (PNEUBEVAX 14TM; BE-PCV-14) containing two additional epidemiologically important serotypes (22F and 33F) in comparison to PCV-13 was evaluated in infants.
Methods This is a pivotal phase-3 single blind randomized active-controlled study conducted at 12 sites across India in 6-8 weeks old healthy infants in 6-10-14 weeks dosing schedule to assess immunogenic non-inferiority and safety of a candidate BE-PCV-14. In total, 1290 infants were equally randomized to receive either BE-PCV-14 or PCV-13. Solicited local reactions and systemic events, adverse events (AEs), serious AEs (SAEs) and medically attended AEs (MAAEs) were recorded. Immunogenicity was assessed by measuring anti-PnCPS IgG concentration and functional antibody titers by opsonophagocytic activity (OPA), one month after completing three dose schedule. Cross protection to serotype 6A offered by serotype 6B was also assessed in this study.
Findings The safety profile of BE-PCV-14 was comparable to PCV-13 vaccine. Majority of reported AEs were mild in nature and no severe or serious AEs were reported. Primary immunogenicity objective was met for all 14 serotypes. For the twelve common serotypes non-inferiority to those 12 serotypes in PCV-13 was met. Additional serotypes in BE-PCV-14 (22F and 33F) also met NI criteria as defined by WHO TRS-977. A significant seroconversion, about 69% for serotype 6A was observed even though this antigen was not present in BE-PCV-14. This indicates that serotype 6B of BE-PCV-14 cross protects serotype 6A. BE-PCV-14 also elicited comparable serotype specific functional OPA immune responses to all the serotypes in PCV-13.
Interpretations BE-PCV-14 was found to be safe and induced robust and functional serotype specific immune responses to all 14 serotypes. All serotype-specific IgG responses were comparable to those in PCV-13. These findings suggest that BE-PCV-14 can be safely administered to infants and achieve protection against pneumococcal disease caused by serotypes covered in the vaccine.
The study was prospectively registered with clinical trial registry of India-CTRI/2020/02/023129
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
CTRI202002023129
Funding Statement
Biological E Limited
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the principles defined in the Declaration of Helsinki, International Conference on Harmonization guidelines (Good Clinical Practices), and the new drug and clinical trial rules, 2019. The investigational review board or ethics committee at each study site approved the protocol. 1. Dr. G. Bala Kishor, St.Theresas Hospital (STH), Erragadda Main Road, Czech Colony Sanath Nagar, Hyderabad 500038, Telangana, India 2. Dr. S. Prashanth, Cheluvamba Hospital, Irwin Rd, Devraj Mohalla, Mysure 570001, Karnataka, India 3. Dr. Ramchandra Keshav Dhongade, Sant Dnyaneshwar Medical Education and Research Centre, Pune 4. Dr. Mane Sushant Satish, Grant Medical College and Sir J.J Hospital, J J Marg, Nagpada, Mumbai Central, Mumbai 400008, Maharashtra, India. 5. Dr. M. D. Ravi, JSS Hospital, Mahatma Gandhi Road, Fort Mohalla, Mysuru 570004, Karnataka, India. 6. Dr. Savita Verma, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences and Hospital, Rothak, Haryana, India. 7. Dr. VN Tripathi, Prakhar Hospital, 8, 219, Khalasi Line, Arya Nagar, Kanpur 208002, Uttar Pradesh, India 8. Dr. P Venugopal, Department of Paediatric, King George Hospital Collectorate Junction, Maharanipeta Visakhapatnam 530002 .Andhra Pradesh, India. 9.Dr. NS Mahantashetti, KLES Dr. Prabhakar Kore Hospital and Medical Research Centre, J N Medical College, Nehru Nagar, Belagavi 590010,Karnataka, India. 10. Dr. Jai Prakash Narayan, JLN Medical College, Kala Bagh, Ajmer 305001, Rajasthan, India 11. Dr. Abhishek T. Chavan, Jeevan Rekha Hospital, Dr. B R Ambedkar Road, Belagavi 590002, Karnataka, India 12. Dr. Srimukhi Anumolu, Vignesh Women and Children Hospital, Prajasakti Nagar, Vijayawada, Andhra Pradesh, India.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
